Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
Hamauchi S, Yasui H, Yokota T, Tsushima T, Fushiki K, Naito T, Ono A, Kado N, Onozawa Y, Murakami H, Takahashi T, Hirashima Y, Mori K, Yamazaki K. Hamauchi S, et al. Among authors: onozawa y. Invest New Drugs. 2024 Dec;42(6):655-663. doi: 10.1007/s10637-024-01480-w. Epub 2024 Oct 26. Invest New Drugs. 2024. PMID: 39460855 Clinical Trial.
Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.
Imamura Y, Kiyota N, Tahara M, Kodaira T, Hayashi R, Nishino H, Asada Y, Mitani H, Iwae S, Nishio N, Onozawa Y, Hanai N, Ohkoshi A, Hara H, Monden N, Nagaoka M, Minami S, Kitabayashi R, Sasaki K, Homma A; Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG‐HNCSG). Imamura Y, et al. Among authors: onozawa y. Cancer Med. 2024 Sep;13(18):e70235. doi: 10.1002/cam4.70235. Cancer Med. 2024. PMID: 39348265 Free PMC article. Clinical Trial.
Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
Shimizu H, Kodaira T, Kiyota N, Hayashi R, Nishino H, Asada Y, Mitani H, Hirayama Y, Onozawa Y, Nishio N, Hanai N, Ohkoshi A, Hara H, Monden N, Nagaoka M, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Uemura H, Shiga K, Nakahira M, Asakage T, Saito Y, Sasaki K, Kitabayashi R, Ishikura S, Nishimura Y, Tahara M. Shimizu H, et al. Among authors: onozawa y. Oral Oncol. 2024 Oct;157:106976. doi: 10.1016/j.oraloncology.2024.106976. Epub 2024 Aug 6. Oral Oncol. 2024. PMID: 39111143
Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy.
Suzuki S, Yokota T, Notsu A, Hamauchi S, Onozawa Y, Fushiki K, Oshima K, Kawakami T, Tsushima T, Yasui H, Ogawa H, Onoe T, Kawatani K, Yamazaki K. Suzuki S, et al. Among authors: onozawa y. Oncologist. 2024 Oct 3;29(10):e1315-e1323. doi: 10.1093/oncolo/oyae167. Oncologist. 2024. PMID: 38979778 Free PMC article.
253 results